Showing 2271-2280 of 9355 results for "".
- Tapinarof Demonstrates Consistent Efficacy Across Pediatric and Adult Patients With Atopic Dermatitishttps://practicaldermatology.com/news/tapinarof-demonstrates-consistent-efficacy-across-pediatric-and-adult-patients-with-atopic-dermatitis/2487900/Organon will present new data from a post hoc pooled analysis of the Phase 3 ADORING 1 and ADORING 2 trials at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting in Minneapolis, Minnesota, showing that tapinarof (VTAMA) cream 1% produced early and consistent improvements in patients
- Psychological Burden of Atopic Dermatitis Appears Greatest in Children and Adolescentshttps://practicaldermatology.com/news/psychological-burden-of-atopic-dermatitis-appears-greatest-in-children-and-adolescents/2487888/Children and adolescents with atopic dermatitis (AD) may experience a greater psychological burden than adults with the disease, according to a systematic review and meta-analysis published in Frontiers in Public Health.¹ However, investigators cautioned
- Oral Vitamin D Associated With Faster Recovery From Cancer Therapy Skin Toxicitieshttps://practicaldermatology.com/news/oral-vitamin-d-associated-with-faster-recovery-from-cancer-therapy-skin-toxicities/2487854/High-dose oral vitamin D may offer a promising supportive care option for patients experiencing chemotherapy- and radiation-induced skin toxicities, according to a multicenter case series in JAMA Dermatology.
- American Pharmacists Association Urges FDA to Put Patient Safety First in Peptide Reviewhttps://practicaldermatology.com/news/apha-urges-fda-to-put-patient-safety-first-in-peptide-review/2487836/The American Pharmacists Association (APhA) is urging the US Food and Drug Administration (FDA) to prioritize patient safety, scientific evidence, and regulatory oversight in its decision-making process, according to
- Zasocitinib Demonstrates Strong Week 16 Responses Across High-Impact Psoriasis Siteshttps://practicaldermatology.com/news/zasocitinib-demonstrates-strong-week-16-responses-across-high-impact-psoriasis-sites/2487716/Takeda announced new secondary analyses from its pivotal Phase 3 LATITUDE PsO 3001 and 3002 trials showing that the investigational oral TYK2 inhibitor zasocitinib (TAK-279) achieved high rates of skin clearance in adults with moderate-to-severe plaque psoriasis a
- New Data Support 24-Week Abrocitinib Tapering in Controlled ADhttps://practicaldermatology.com/news/new-data-support-24-week-abrocitinib-tapering-in-controlled-ad/2487773/New data published in the Journal of the American Academy of Dermatology suggests tapering abrocitinib may be a feasible strategy for patients with moderate-to-severe atopic dermatitis (AD) who have achieved an adequate clin
- CuralysMD Launches Steroid-Free Eczema Lotion Focused on Skin Barrier Supporthttps://practicaldermatology.com/news/curalysmd-launches-steroid-free-eczema-lotion-focused-on-skin-barrier-support/2487770/CuralysMD announced the unveiling of a new over-the-counter eczema skin protectant lotion designed to support skin barrier repair in patients with mild to moderate eczema. The steroid-free formulation contains colloidal oatme
- LEO Pharma Reports Positive Phase 2 Pediatric Data for Tralokinumab in Atopic Dermatitishttps://practicaldermatology.com/news/leo-pharma-reports-positive-phase-2-pediatric-data-for-tralokinumab-in-atopic-dermatitis/2487767/LEO Pharma has announced positive topline results from the Phase 2 TRAPEDS-1 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD).
- Consensus Panel Offers First Standardized Imaging Framework for High-Risk CSCChttps://practicaldermatology.com/news/consensus-panel-offers-first-standardized-imaging-framework-for-high-risk-cscc/2487708/A multidisciplinary panel of experts has developed consensus recommendations to help standardize staging and surveillance imaging for patients with localized cutaneous squamous cell carcinoma (cSCC), publishing the recommendations online in
- FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With ADhttps://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-005-in-infants-with-atopic-dermatitis/2487703/The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to mode